Assetmark, Inc Supernus Pharmaceuticals, Inc. Transaction History

Assetmark, Inc

$45.6 Billion
Q3 2025

A detailed history of Assetmark, Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 39,724 shares of SUPN stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,724

Previous 36,704 8.23%

Holding current value

$1.79 Million

Previous $1.16 Million 64.19%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 06, 2025	BUY	$31.45 - $47.79 $94,979 - $144,325	3,020 Added 8.23%	39,724 $1.9 Million
Q2 2025 Aug 04, 2025	SELL	$30.29 - $33.43 $38,135 - $42,088	-1,259 Reduced 3.32%	36,704 $1.16 Million
Q1 2025 May 06, 2025	BUY	$31.17 - $40.0 $147,995 - $189,920	4,748 Added 14.29%	37,963 $1.24 Million
Q4 2024 Feb 06, 2025	SELL	$31.89 - $37.83 $7,239 - $8,587	-227 Reduced 0.68%	33,215 $1.2 Million
Q3 2024 Nov 01, 2024	BUY	$25.77 - $35.16 $23,399 - $31,925	908 Added 2.79%	33,442 $1.04 Million

Q2 2024 Aug 13, 2024	BUY	$25.99 - $33.85 $37,217 - $48,473	1,432 Added 4.6%	32,534 $870,000
Q1 2024 May 06, 2024	BUY	$27.11 - $35.17 $38,035 - $49,343	1,403 Added 4.72%	31,102 $1.06 Million
Q4 2023 Feb 09, 2024	BUY	$22.72 - $29.68 $25,469 - $33,271	1,121 Added 3.92%	29,699 $859,000
Q3 2023 Oct 27, 2023	BUY	$27.57 - $32.91 $17,341 - $20,700	629 Added 2.25%	28,578 $787,000
Q2 2023 Aug 11, 2023	BUY	$29.91 - $38.73 $58,503 - $75,755	1,956 Added 7.53%	27,949 $840,000
Q1 2023 May 05, 2023	BUY	$34.93 - $42.03 $49,705 - $59,808	1,423 Added 5.79%	25,993 $941,000
Q4 2022 Feb 10, 2023	BUY	$31.09 - $37.88 $17,348 - $21,137	558 Added 2.32%	24,570 $876,000
Q3 2022 Nov 01, 2022	BUY	$28.79 - $35.41 $636,460 - $782,808	22,107 Added 1160.47%	24,012 $813,000
Q2 2022 Aug 03, 2022	BUY	$25.33 - $34.25 $7,168 - $9,692	283 Added 17.45%	1,905 $55,000
Q1 2022 May 13, 2022	SELL	$28.51 - $32.9 $427 - $493	-15 Reduced 0.92%	1,622 $52,000
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $1,397 - $1,813	53 Added 3.35%	1,637 $48,000
Q3 2021 Nov 12, 2021	BUY	$23.54 - $31.39 $353 - $470	15 Added 0.96%	1,584 $42,000
Q2 2021 Aug 16, 2021	SELL	$26.72 - $33.19 $80 - $99	-3 Reduced 0.19%	1,569 $48,000
Q1 2021 May 14, 2021	BUY	$24.15 - $31.45 $1,956 - $2,547	81 Added 5.43%	1,572 $41,000
Q4 2020 Feb 10, 2021	BUY	$17.7 - $25.81 $2,849 - $4,155	161 Added 12.11%	1,491 $38,000
Q3 2020 Nov 13, 2020	BUY	$20.2 - $25.05 $8,484 - $10,521	420 Added 46.15%	1,330 $28,000
Q2 2020 Aug 11, 2020	BUY	$17.09 - $24.89 $14,458 - $21,056	846 Added 1321.88%	910 $22,000
Q1 2020 May 12, 2020	SELL	$14.45 - $24.69 $317 - $543	-22 Reduced 25.58%	64 $1,000
Q4 2019 Feb 11, 2020	BUY	$19.93 - $29.13 $159 - $233	8 Added 10.26%	86 $2,000
Q3 2019 Nov 13, 2019	BUY	$25.47 - $33.37 $1,986 - $2,602	78 New	78 $2,000
Q1 2018 May 16, 2018	SELL	$37.15 - $46.9 $631 - $797	-17 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$36.4 - $42.6 $618 - $724	17	17 $1,000

Others Institutions Holding SUPN

# of Institutions

330

Shares Held

60.2M

Call Options Held

234K

Put Options Held

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.41B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account